4SC nominates NFkB development candidate and presents new data

Announced today that it would be presenting positive data from its NFkB project at the "5th GTCBio Cytokines & Inflammation Conference". The conference is scheduled to take place from January 29-30, 2007, in Breckenridge, Colorado.

PLANEGG, Germany | Jan 23, 2006 |
4SC AG, a drug discovery and development company based in Martinsried, Germany (Frankfurt, Prime Standard: VSC), announced today that it would be presenting positive data from its NFkB project at the "5th GTCBio Cytokines & Inflammation Conference". The conference is scheduled to take place from January 29-30, 2007, in Breckenridge, Colorado.

In studies using an animal model for rheumatoid arthritis, one of 4SC's NFkB inhibitors demonstrated very promising activity. This substance, which has been termed SC71570, proved to be even more active than the commercially available reference compound, methotrexate. At present, methotrexate is considered the gold standard in basic therapy for rheumatoid arthritis. 4SC AG has therefore nominated SC71570 as a development substance to promote its further development towards clinical trials. This will give the inhibitor a chance to achieve marketability as an innovative, orally available and small molecular therapeutic agent with a novel mode of action in the treatment of chronic disorders such as rheumatoid arthritis or inflammatory intestinal disorders.

SC71570 belongs to a new class of drug candidates that have been identified by 4SC AG. These substances have an inhibitory effect on the NFkB signalling pathway, a central mechanism in inflammatory processes. The inhibitors are able to control the activation of human immune cells. Possible therapeutic applications include chronic disorders requiring intensive therapy, such as rheumatoid arthritis, chronic intestinal inflammation (Crohn's disease, ulcerative colitis) or chronic inflammation of the respiratory passages. In the medium term, an application for cancer therapy or the treatment of infectious viral diseases is also conceivable.

"With the nomination of this development candidate, we have reached an important milestone on the path to clinical trials," explains Daniel Vitt, CSO of 4SC AG. He estimates that, because of its wide spectrum of applications, such an agent holds the promise, if successful, of a peak sales potential of approximately EUR 800 million. He also describes SC71570 as an ideal supplement to 4SC's DHODH inhibitor SC12267, which is currently undergoing a phase IIa clinical trial in the treatment of rheumatoid arthritis.

The scientific data for the new development substance will be presented, as part of the GTCBio Conference, on a poster with the title "Novel Orally Active NFkB Inhibitors for the Treatment of Inflammatory Diseases".

About 4SC
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 59, the company develops novel drug candidates for inflammatory diseases and cancer using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC AG uses its patented technology platform to create a sustainable product pipeline for active agents that are developed in early clinical phases ("proof of concept") and subsequently result in upfront and milestone payments as well as participation in sales generated by out-licensed products to the pharmaceutical industry. There are currently five projects in the pipeline. The first project on the treatment of rheumatoid arthritis is currently undergoing clinical phase IIa. Three other product candidates are in pre-clinical development and another project is in the research stage. Furthermore, the company has its technology platform in co-operation projects with biotech and pharma companies and is already generating initial revenues.

Legal Note
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.


La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up